Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Peptides and Non Peptides of Oncologic and Neuroendocrine Relevance
Describes the ability of a series of endocrine-derived compounds, i.e. CHRH, LHRH, somatostatin, anti-androgens, and aromatase inhibitors to exert a direct anti-neoplastic activity or to potentiate the activity of traditional chemotherapeutic agents on neuroendocrine and solid tumors. In addition, a new class of potent GH-releasers, GSHs/Ghrelin, endowed with important endocrine and extra-endcocrine action, is presented. Therefore, in addition to traditional chemotherapy, characterized by high toxicity and non-selective action on tumoral cells, the reader can find a new approach with more selective, less cytotoxic endocrine derived compounds.
The Peptidergic Neuron
Neuropeptides rank among the phylogenetically oldest interneuronal signal substances. In the concept of neuro-secretion they were identified as neurohormones by which - via the blood - the brain regulates peripheral functions. It is now evident that the neuropeptides act as neurotransmitters/-modulators, as (neuro-)hormones, and paracrine or autocrine signal substances in diverse parts of the body. This book reviews, in several comprehensive articles written by distinguished specialists, the state of the art in the field of neuropeptides and peptidergic neurons. Special topics concern molecular aspects of processing, release and degradation of neuropeptides, receptors and signal transduction, comparative and behavioural aspects, and immunoregulatory effects of neuropeptides and their involvement on pathology of the central nervous system.
Neuroendocrine Perspectives
In the first section of this volume, we have attempted to bring together some of the papers that reflect exciting new areas of development in relation to neuroendocrine investigation. Very recently, specific nucleotide recognition sequences for thyroid hormones, steroid hormones and the fundamental intracellular regulator, cyclic AMP, have been determined. In this section, the preliminary characterization and investigation of the nuclear binding proteins that mediate the actions of cAMP are described. Not only does this represent an important advance in cell biology, but it may represent a further level of alteration in control in normal and disease states. Intercellular pituitary "cross tal...
Small Peptides
Pharmacochemistry Library, Volume 19: Small Peptides: Chemistry, Biology, and Clinical Studies focuses on the processes, reactions, properties, and characteristics of peptides, including analogues and proteases. The publication first takes a look at angiotensin II and bombesin/gastrin-releasing peptide. Topics include conformationally restricted analogues of bombesin, non-peptide antagonists of angiotensin II, receptor subtypes of angiotensin II, and bombesin/GRP antagonists and cancer. The text then elaborates on bradykinin, cholecystokinin, and enkephalin analogues. The manuscript examines luteinizing hormone releasing hormone and somatostatin. Topics include enzymic degradation of somatostatin and analogues, clinical applications of somatostatin analogues, and pharmacological and clinical studies with LHRH agonists and antagonists. The formulation of peptides and inhibitors of aspartyl proteases are also mentioned. The book is a valuable source of information for chemists, biologists, and readers interested in small peptides.
Integration of Pharmaceutical Discovery and Development
In the late 1980s, it became painfully evident to the pharmaceutical industry that the old paradigm of drug discovery, which involved highly segmented drug - sign and development activities, would not produce an acceptable success rate in the future. Therefore, in the early 1990s a paradigm shift occurred in which drug design and development activities became more highly integrated. This new str- egy required medicinal chemists to design drug candidates with structural f- tures that optimized pharmacological (e. g. , high affinity and specificity for the target receptor), pharmaceutical (e. g. , solubility and chemical stability), bioph- maceutical (e. g. , cell membrane permeability), and m...
Octreotide: from Basic Science to Clinical Medicine
`This book is the best available on octreotide from a combined basic science and clinical perspective.'Gut
The Pituitary
The pituitary, albeit a small gland, is known as the "master gland" of the endocrine system and contributes to a wide spectrum of disorders, diseases, and syndromes. Since the publication of the second edition of The Pituitary, in 2002, there have been major advances in the molecular biology research of pituitary hormone production and action and there is now a better understanding of the pathogenesis of pituitary tumors and clinical syndromes resulting in perturbation of pituitary function. There have also been major advances in the clinical management of pituitary disorders. Medical researchers and practitioners now better understand the morbidity and mortality associated with pituitary ho...
Anticipating and Assessing Health Care Technology, Volume 2
As noted in the Foreword, this report is the second of several volumes resulting from this study of future health care technology. The purpose of the study, as formulated by the STG, was to analyze future health care technology. Part of the task was to develop an 'early warning system' for health care technology. The primary goal of the project was to develop a list or description of a number of possible and probable future health care technologies, as well as information on their importance. Within the limits of time and money, this has been done. This report is the description of anticipated future health care technologies. However, given the vast number of possible future health care technologies, complete information on the importance of each area could not be developed in any depth for all technology. Therefore, four specific technologies were chosen and were prospectively assessed. These future technologies were examined in more depth, looking particularly at their future health and policy implications. Subsequently, the project was extended to September 1987, and two additional technologies are being assessed.
Pharmacogenomics
"Summarizes the history of, and available applications, techniques, and approaches to, pharmacogenomics--improving efficacy and tolerance to pharmaceutical compounds, evaluating pharmacogenomics on clinical trial design, and increasing the chances of successful clinical trials and patient outcomes. Compares pharmacogenomics to pharmacogenetics, focusing on the essential components that incorporate individual genetic variations to drug regimens resulting in different responses to therapeutics."
